<ul>
<li>生物科技正在升温——这两只热门股票脱颖而出</li>
</ul>
<p>Axsome Therapeutics NASDAQ: AXSM 的高管表示，公司正在为 6 月推出 AUVELITY 治疗阿尔茨海默病激动症做准备，同时继续扩大在重度抑郁症领域的推进，提到广泛的支付方覆盖、更大的销售团队以及他们所描述的差异化临床特征。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<p>在一次公司介绍会上，首席运营官 Mark Jacobson 和首席财务官 Nick Pizzie 讨论了新 AUVELITY 适应症的近期批准、公司的商业战略以及其他资产的更新，包括 SYMBRAVO 和 SUNOSI。</p>
<h2>AUVELITY 推出策略集中于与抑郁症市场的重叠</h2>
<ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
<p>Jacobson 表示，阿尔茨海默病激动症的新标签 “非常清晰”，为 Axsome 的商业团队提供了教育处方者的空间，涵盖新的适应症和 AUVELITY 现有的重度抑郁症适应症。他表示，阿尔茨海默病激动症代表了一个严重的未满足需求，同时也与抑郁症治疗形成了商业重叠。</p>
<p>Pizzie 表示，AUVELITY 在重度抑郁症的推出已进入第 14 个季度。Axsome 最初以 160 名销售代表开始这一推出，后来扩展到 260 名，再到 300 名，现在在阿尔茨海默病激动症推出之前，销售团队已增加到 630 名代表，以应对重度抑郁症的增长趋势。</p>
<ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p>根据 Pizzie 的说法，AUVELITY 在重度抑郁症中的支付方覆盖率为 86%，其中 56% 为第一线或首次转换。他表示，该产品目前在抗抑郁药市场的份额为 0.2%，年化销售额超过 6 亿美元，同时在 NBRx 市场的份额为 0.3%。</p>
<p>Jacobson 表示，公司对适应症之间协同作用的内部看法，更多是基于处方者层面的分析，而不是其他中枢神经系统药物的类比。他表示，长期护理是一个关键的重叠领域，因为居民和阿尔茨海默病激动症患者中抑郁症的发生率很高。</p>
<p>“长期护理设施中 50% 到 80% 的人都患有抑郁症，而这不是我们过去积极教育或详细说明的领域，” Jacobson 说。</p>
<h2>公司强调阿尔茨海默病激动症的差异化</h2>
<p>在被问及 AUVELITY 在阿尔茨海默病激动症中的竞争地位时，Jacobson 表示，该药物的差异化始于其机制，他将其描述为针对 NMDA 和 sigma-1。他表示，这一特征与目前在患者群体中使用的标示和非标示药物治疗不同。</p>
<p>Jacobson 表示，标签包括平行组疗效数据，显示该产品作用迅速，2 到 3 周内即可见效，以及显示长期效果的复发预防数据。他还强调了耐受性，引用了不良事件的低发生率，并表示该标签不包括针对该患者群体的黑框警告。</p>
<p>“我们没有看到镇静。我们没有看到死亡信号。我们没有看到跌倒信号，” Jacobson 说，并补充说，患者群体中列出的最常见不良事件是头晕和消化不良。</p>
<p>Jacobson 表示，630 人的销售团队将同时推广阿尔茨海默病激动症和重度抑郁症，目标决策将根据提供者类型、账户组合和地理位置来驱动。每位客户经理将有一组目标，专注于重度抑郁症、阿尔茨海默病激动症或两者。</p>
<h2>预计医疗保险 D 部分覆盖将支持推出</h2>
<p>Pizzie 表示，Axsome 预计约 80% 的阿尔茨海默病激动症处方将归入医疗保险 D 部分。他表示，公司目前在 D 部分的覆盖率为 100%，其中 75% 的患者无需事先授权，且为第一线或首次转换的访问。对于剩余的 25%，Pizzie 表示，公司预计大多数事先授权将仅限于确认适应症。</p>
<p>关于毛利与净利的动态，Pizzie 表示，Axsome 预计 D 部分的净价格将略好于商业渠道，因为 D 部分不允许共付覆盖。</p>
<p>对于长期护理，Pizzie 表示，630 名代表中的一部分将专注于该渠道，并将更像关键账户经理，而不是传统的专业或初级护理代表。他表示，他们的角色将包括教育设施有关支付方的覆盖，并与支持中心的药房和医疗专业人员建立关系。</p>
<p>Jacobson 补充说，Axsome 一直在通过其现有的重度抑郁症业务准备供应链基础设施，以确保处方能够在开具时得到满足。</p>
<h2>重度抑郁症增长计划包括初级护理和 DTC 投资</h2>
<p>在重度抑郁症方面，Jacobson 表示，公司对长期预期基于初级护理采用、患者表现和临床医生反馈的当前趋势。他表示，Axsome 正在进一步投资于初级护理，并不认为其目标依赖于狭窄的患者特征。</p>
<p>Pizzie 指出，公司在儿科适应症方面的独占权将持续到 2039 年初，并表示 AUVELITY 仍处于其商业生命周期的早期阶段。他表示，Axsome 一直在 “打下根基”，现在正在通过更大的销售团队和直接面向消费者的广告增加投资。</p>
<p>关于 DTC 支出，Pizzie 表示，Axsome 在去年第四季度开始广告，并对传统线性电视和数字电视之间的组合有了更多了解。新的广告活动于 3 月开始，预计将持续到今年剩余时间，尽管 Pizzie 表示支出将保持谨慎。</p>
<p>Jacobson 表示，公司仍然将销售团队视为最佳投资回报机会，DTC 和其他推广渠道作为支持元素。</p>
<h2>SYMBRAVO 和 SUNOSI 的最新动态</h2>
<p>在讨论 SYMBRAVO 时，Pizzie 表示，随着支付方的接入改善，预计收入确认将出现拐点。他提到第一季度取得了一个 “不错的胜利”，并表示处方的环比增长约为 36%。他表示，关于该产品的反馈是积极的，包括疗效和安全性，并指出 Axsome 正在将 SYMBRAVO 的销售团队从大约 100 名代表扩大。</p>
<p>Jacobson 表示，SYMBRAVO 所处的市场与抑郁症不同，特别是在接入和治疗动态方面，并且 Axsome 一直在使用数据驱动的方法来理解临床医生的反馈和市场运作，以便在进一步投资之前进行评估。</p>
<p>关于 SUNOSI 在注意力缺陷/多动症中的应用，Jacobson 表示，成人试验的疗效与兴奋剂在绝对变化基础上相符，并且该产品具有独特的耐受性和排药特征。他表示，Axsome 正在儿童和青少年中启动两个试验，并将在年内提供更新。</p>
<p>“我们只需要完成临床项目，” Jacobson 说。</p>
<h2>关于 Axsome Therapeutics NASDAQ: AXSM</h2>
<p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在解决抑郁症、偏头痛、嗜睡症和纤维肌痛等领域未满足的医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制并改善患者的治疗效果。</p>
<p>Axsome 的产品管线包括多个晚期和已批准的产品候选者。</p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>Axsome Therapeutics 计划于 6 月推出用于阿尔茨海默病激动症的 AUVELITY，同时还将扩大在重度抑郁症（MDD）方面的努力。该公司已将销售团队扩大至 630 名代表，并报告 AUVELITY 在 MDD 方面的支付方接入率为 86%。该药物独特的机制靶向 NMDA 和 sigma-1，使其与现有治疗方法有所区别。Axsome 预计 80% 的处方将由医疗保险 D 部分覆盖，重点关注长期护理设施。该公司旨在利用阿尔茨海默病激动症与 MDD 治疗之间的协同效应</p>

<ul>
<li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技正在升温——这两只热门股票脱颖而出</li>
</ul>
</div><p>Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clinical profile.</p>
<div class="lb-trans"><p>Axsome Therapeutics NASDAQ: AXSM 的高管表示，公司正在为 6 月推出 AUVELITY 治疗阿尔茨海默病激动症做准备，同时继续扩大在重度抑郁症领域的推进，提到广泛的支付方覆盖、更大的销售团队以及他们所描述的差异化临床特征。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><p>Speaking at a company presentation, Chief Operating Officer Mark Jacobson and Chief Financial Officer Nick Pizzie discussed the recent approval of the new AUVELITY indication, the company’s commercial strategy and updates on other assets including SYMBRAVO and SUNOSI.</p>
<div class="lb-trans"><p>在一次公司介绍会上，首席运营官 Mark Jacobson 和首席财务官 Nick Pizzie 讨论了新 AUVELITY 适应症的近期批准、公司的商业战略以及其他资产的更新，包括 SYMBRAVO 和 SUNOSI。</p>
</div><h2>AUVELITY Launch Strategy Centers on Overlap With Depression Market</h2>
<div class="lb-trans"><h2>AUVELITY 推出策略集中于与抑郁症市场的重叠</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
</div><p>Jacobson said the new label for Alzheimer’s disease agitation is “incredibly clean” and gives Axsome’s commercial team room to educate prescribers across both the new indication and AUVELITY’s existing major depressive disorder, or MDD, indication. He said Alzheimer’s disease agitation represents a serious unmet need, while also creating commercial overlap with depression treatment.</p>
<div class="lb-trans"><p>Jacobson 表示，阿尔茨海默病激动症的新标签 “非常清晰”，为 Axsome 的商业团队提供了教育处方者的空间，涵盖新的适应症和 AUVELITY 现有的重度抑郁症适应症。他表示，阿尔茨海默病激动症代表了一个严重的未满足需求，同时也与抑郁症治疗形成了商业重叠。</p>
</div><p>Pizzie said AUVELITY is 14 quarters into its MDD launch. Axsome began that launch with 160 sales representatives, later expanded to 260 and then 300, and has now increased the field force to 630 representatives ahead of the Alzheimer’s disease agitation launch and in response to the trajectory in MDD.</p>
<div class="lb-trans"><p>Pizzie 表示，AUVELITY 在重度抑郁症的推出已进入第 14 个季度。Axsome 最初以 160 名销售代表开始这一推出，后来扩展到 260 名，再到 300 名，现在在阿尔茨海默病激动症推出之前，销售团队已增加到 630 名代表，以应对重度抑郁症的增长趋势。</p>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p>According to Pizzie, AUVELITY has 86% payer access in MDD, with 56% either first line or first switch. He said the product currently has 0.2% of the total antidepressant market and is annualizing at more than $600 million, while holding 0.3% of the NBRx market.</p>
<div class="lb-trans"><p>根据 Pizzie 的说法，AUVELITY 在重度抑郁症中的支付方覆盖率为 86%，其中 56% 为第一线或首次转换。他表示，该产品目前在抗抑郁药市场的份额为 0.2%，年化销售额超过 6 亿美元，同时在 NBRx 市场的份额为 0.3%。</p>
</div><p>Jacobson said the company’s internal view of synergy between indications is based less on analogs from other central nervous system drugs and more on prescriber-level analysis. He said long-term care is a key area of overlap because of high rates of depression among residents and among patients with Alzheimer’s disease agitation.</p>
<div class="lb-trans"><p>Jacobson 表示，公司对适应症之间协同作用的内部看法，更多是基于处方者层面的分析，而不是其他中枢神经系统药物的类比。他表示，长期护理是一个关键的重叠领域，因为居民和阿尔茨海默病激动症患者中抑郁症的发生率很高。</p>
</div><p>“Fifty percent to 80% of individuals in long-term care facilities are depressed, and that’s not an area that we’ve actively educated in the past or detailed in,” Jacobson said.</p>
<div class="lb-trans"><p>“长期护理设施中 50% 到 80% 的人都患有抑郁症，而这不是我们过去积极教育或详细说明的领域，” Jacobson 说。</p>
</div><h2>Company Highlights Differentiation in Alzheimer’s Disease Agitation</h2>
<div class="lb-trans"><h2>公司强调阿尔茨海默病激动症的差异化</h2>
</div><p>Asked about the competitive position of AUVELITY in Alzheimer’s disease agitation, Jacobson said the drug’s differentiation starts with its mechanism, which he described as targeting NMDA and sigma-1. He said that profile is distinct from on- and off-label pharmacotherapies currently used in the patient population.</p>
<div class="lb-trans"><p>在被问及 AUVELITY 在阿尔茨海默病激动症中的竞争地位时，Jacobson 表示，该药物的差异化始于其机制，他将其描述为针对 NMDA 和 sigma-1。他表示，这一特征与目前在患者群体中使用的标示和非标示药物治疗不同。</p>
</div><p>Jacobson said the label includes parallel-group efficacy data showing that the product works quickly, with separation seen at two to three weeks, as well as relapse-prevention data demonstrating duration of effect over longer periods. He also emphasized tolerability, citing low rates of adverse events and saying the label does not include a boxed warning for this patient population.</p>
<div class="lb-trans"><p>Jacobson 表示，标签包括平行组疗效数据，显示该产品作用迅速，2 到 3 周内即可见效，以及显示长期效果的复发预防数据。他还强调了耐受性，引用了不良事件的低发生率，并表示该标签不包括针对该患者群体的黑框警告。</p>
</div><p>“We didn’t see sedation. We don’t see a mortality signal. We don’t see a fall signal,” Jacobson said, adding that the most common adverse events listed for the patient population are dizziness and dyspepsia.</p>
<div class="lb-trans"><p>“我们没有看到镇静。我们没有看到死亡信号。我们没有看到跌倒信号，” Jacobson 说，并补充说，患者群体中列出的最常见不良事件是头晕和消化不良。</p>
</div><p>Jacobson said the 630-person sales force will promote both Alzheimer’s disease agitation and MDD, with targeting decisions driven by provider type, account mix and geography. Each account manager will have a blend of targets focused on MDD, Alzheimer’s disease agitation or both.</p>
<div class="lb-trans"><p>Jacobson 表示，630 人的销售团队将同时推广阿尔茨海默病激动症和重度抑郁症，目标决策将根据提供者类型、账户组合和地理位置来驱动。每位客户经理将有一组目标，专注于重度抑郁症、阿尔茨海默病激动症或两者。</p>
</div><h2>Medicare Part D Coverage Expected to Support Launch</h2>
<div class="lb-trans"><h2>预计医疗保险 D 部分覆盖将支持推出</h2>
</div><p>Pizzie said Axsome expects about 80% of Alzheimer’s disease agitation prescriptions to fall under Medicare Part D. He said the company currently has 100% covered lives in Part D, with 75% of those lives having no prior authorization and first-line or first-switch access. For the remaining 25%, Pizzie said the company expects most prior authorizations to be limited to confirmation of indication.</p>
<div class="lb-trans"><p>Pizzie 表示，Axsome 预计约 80% 的阿尔茨海默病激动症处方将归入医疗保险 D 部分。他表示，公司目前在 D 部分的覆盖率为 100%，其中 75% 的患者无需事先授权，且为第一线或首次转换的访问。对于剩余的 25%，Pizzie 表示，公司预计大多数事先授权将仅限于确认适应症。</p>
</div><p>On gross-to-net dynamics, Pizzie said Axsome expects net price in Part D to be slightly better than in the commercial channel because copay coverage is not allowed in Part D.</p>
<div class="lb-trans"><p>关于毛利与净利的动态，Pizzie 表示，Axsome 预计 D 部分的净价格将略好于商业渠道，因为 D 部分不允许共付覆盖。</p>
</div><p>For long-term care, Pizzie said a portion of the 630 representatives will be dedicated to that channel and will function more like key account managers than traditional specialty or primary care representatives. He said their role will include educating facilities about payer access and building relationships with pharmacies and health care professionals who support the centers.</p>
<div class="lb-trans"><p>对于长期护理，Pizzie 表示，630 名代表中的一部分将专注于该渠道，并将更像关键账户经理，而不是传统的专业或初级护理代表。他表示，他们的角色将包括教育设施有关支付方的覆盖，并与支持中心的药房和医疗专业人员建立关系。</p>
</div><p>Jacobson added that Axsome has been preparing supply chain infrastructure through its existing MDD business to ensure prescriptions can be filled when written.</p>
<div class="lb-trans"><p>Jacobson 补充说，Axsome 一直在通过其现有的重度抑郁症业务准备供应链基础设施，以确保处方能够在开具时得到满足。</p>
</div><h2>MDD Growth Plan Includes Primary Care and DTC Investment</h2>
<div class="lb-trans"><h2>重度抑郁症增长计划包括初级护理和 DTC 投资</h2>
</div><p>In MDD, Jacobson said the company’s long-term expectations are based on current trends in primary care adoption, patient performance and clinician feedback. He said Axsome is investing further in primary care and does not view its targets as dependent on a narrow patient profile.</p>
<div class="lb-trans"><p>在重度抑郁症方面，Jacobson 表示，公司对长期预期基于初级护理采用、患者表现和临床医生反馈的当前趋势。他表示，Axsome 正在进一步投资于初级护理，并不认为其目标依赖于狭窄的患者特征。</p>
</div><p>Pizzie noted that the company has exclusivity through early 2039 with pediatric indications and said AUVELITY is still early in its commercial life. He said Axsome has been “laying the roots and the foundation” and is now increasing investment with the larger sales team and direct-to-consumer advertising.</p>
<div class="lb-trans"><p>Pizzie 指出，公司在儿科适应症方面的独占权将持续到 2039 年初，并表示 AUVELITY 仍处于其商业生命周期的早期阶段。他表示，Axsome 一直在 “打下根基”，现在正在通过更大的销售团队和直接面向消费者的广告增加投资。</p>
</div><p>On DTC spending, Pizzie said Axsome began advertising in the fourth quarter of last year and has learned more about the mix between traditional linear television and digital TV. A new campaign began in March and is expected to continue through the rest of the year, though Pizzie said spending will remain disciplined.</p>
<div class="lb-trans"><p>关于 DTC 支出，Pizzie 表示，Axsome 在去年第四季度开始广告，并对传统线性电视和数字电视之间的组合有了更多了解。新的广告活动于 3 月开始，预计将持续到今年剩余时间，尽管 Pizzie 表示支出将保持谨慎。</p>
</div><p>Jacobson said the company still views the sales force as its best return-on-investment opportunity, with DTC and other promotional channels serving as supporting elements.</p>
<div class="lb-trans"><p>Jacobson 表示，公司仍然将销售团队视为最佳投资回报机会，DTC 和其他推广渠道作为支持元素。</p>
</div><h2>Updates on SYMBRAVO and SUNOSI</h2>
<div class="lb-trans"><h2>SYMBRAVO 和 SUNOSI 的最新动态</h2>
</div><p>Discussing SYMBRAVO, Pizzie said an inflection in revenue recognition is expected to come as payer access improves. He cited a “nice win” in the first quarter and said sequential prescription growth was about 36% quarter over quarter. He said feedback on the product has been positive, including on efficacy and safety, and noted that Axsome is expanding the SYMBRAVO sales effort from an average of roughly 100 representatives.</p>
<div class="lb-trans"><p>在讨论 SYMBRAVO 时，Pizzie 表示，随着支付方的接入改善，预计收入确认将出现拐点。他提到第一季度取得了一个 “不错的胜利”，并表示处方的环比增长约为 36%。他表示，关于该产品的反馈是积极的，包括疗效和安全性，并指出 Axsome 正在将 SYMBRAVO 的销售团队从大约 100 名代表扩大。</p>
</div><p>Jacobson said SYMBRAVO operates in a market that is different from depression, particularly in access and treatment dynamics, and that Axsome has been using a data-driven approach to understand clinician feedback and market operations before investing further.</p>
<div class="lb-trans"><p>Jacobson 表示，SYMBRAVO 所处的市场与抑郁症不同，特别是在接入和治疗动态方面，并且 Axsome 一直在使用数据驱动的方法来理解临床医生的反馈和市场运作，以便在进一步投资之前进行评估。</p>
</div><p>On SUNOSI in attention-deficit/hyperactivity disorder, Jacobson said adult trial efficacy was in line with stimulants on an absolute-change basis and that the product has a distinct tolerability and scheduling profile. He said Axsome is starting two trials in children and adolescents and will provide updates during the year.</p>
<div class="lb-trans"><p>关于 SUNOSI 在注意力缺陷/多动症中的应用，Jacobson 表示，成人试验的疗效与兴奋剂在绝对变化基础上相符，并且该产品具有独特的耐受性和排药特征。他表示，Axsome 正在儿童和青少年中启动两个试验，并将在年内提供更新。</p>
</div><p>“We just have to finish the clinical program,” Jacobson said.</p>
<div class="lb-trans"><p>“我们只需要完成临床项目，” Jacobson 说。</p>
</div><h2>About Axsome Therapeutics NASDAQ: AXSM</h2>
<div class="lb-trans"><h2>关于 Axsome Therapeutics NASDAQ: AXSM</h2>
</div><p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在解决抑郁症、偏头痛、嗜睡症和纤维肌痛等领域未满足的医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制并改善患者的治疗效果。</p>
</div><p>Axsome's pipeline includes several late-stage and approved product candidates.</p>
<div class="lb-trans"><p>Axsome 的产品管线包括多个晚期和已批准的产品候选者。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Axsome Therapeutics 计划通过六月推出针对阿尔茨海默症激动的 AUVELITY 产品来扩大市场份额